Tokyo, 13 June 2025

东京，2025年6月13日

—Mitsubishi Research Institute, Inc. (“MRI”) and Astellas Pharma Inc. (“Astellas”) today announced that they have agreed on a memorandum of understanding to provide drug-discovery startups in Japan with support in their efforts to go global. The pair aims to strengthen Japan’s position as a global hub for drug discovery and foster the growth of its startups that can thrive globally..

三菱综合研究所（“MRI”）和安斯泰来制药公司（“Astellas”）今天宣布，双方已就支持日本药物研发初创企业走向全球达成谅解备忘录。双方旨在加强日本作为全球药物研发枢纽的地位，并扶持能够在国际上蓬勃发展的初创企业成长。

The new support represents multiple programs under the Ministry of Health, Labour and Welfare’s Medical Innovation Support Office (MEDISO), which looks to address the lack of practical application of Japan’s advanced life-sciences technologies. Mitsubishi Research Institute has been entrusted to operate MEDISO since 2018 and has been helping promising drug-discovery startups commercialize their intellectual property since..

新的支持代表了厚生劳动省医疗创新支持办公室（MEDISO）旗下的多个项目，该项目旨在解决日本先进生命科学技术缺乏实际应用的问题。自2018年以来，三菱综合研究所受托运营MEDISO，并一直帮助有前途的药物发现初创企业将其知识产权商业化。

“When it comes to practical application, drug-discovery startups need external insights and expertise,” said Hirofumi Suzuki, Executive Officer and General Manager of the Public Innovation Unit at Mitsubishi Research Institute. “Promising startups can substantially speed up the commercialization of their offerings by engaging with globally active pharmaceutical companies early.”.

“在实际应用方面，药物发现初创公司需要外部的洞察力和专业知识，”三菱综合研究所公共创新部门执行官兼总经理铃木宏文表示。“有前途的初创公司可以通过及早与全球活跃的制药公司合作，大幅加快其产品商业化的进程。”

The new partnership looks to leverage the strengths of both companies. MRI will draw from its previous MEDISO work—supporting over twelve hundred startup and academic ventures—and design specific support programs for participants. Astellas Pharma will provide drug-discovery startups participating in the acceleration program conducted through MEDISO with access to laboratory and office space at SakuLab.

新合作关系希望利用两家公司的优势。MRI 将借鉴其之前在 MEDISO 的工作经验——支持超过一千两百家初创企业和学术项目，并为参与者设计特定的支持计划。安斯泰来制药公司将为参加通过 MEDISO 进行的加速计划的药物研发初创公司，提供位于 SakuLab 的实验室和办公空间。

TM

商标

-Tsukuba, located on the premises of the Astellas Tsukuba Research Center. Startups residing in SakuLab

-位于筑波研究中心内的Astellas筑波研究基地。入驻SakuLab的初创公司

TM

商标

-Tsukuba will not only receive support through consultations with Astellas experts in various fields, but will also be able to accelerate their drug discovery research by leveraging networks with fellow residents and Astellas researchers.

-筑波不仅会通过与安斯泰来各领域专家的咨询获得支持，还可以利用与其他入驻者和安斯泰来研究人员的网络，加速其药物发现研究。

“We are very pleased to agree on a memorandum of understanding with MRI. Astellas Pharma is committed to growing and developing innovative ideas and technologies with academia and startups by providing knowledge and experience gained through research and our global network,” said Tadaaki Taniguchi, M.D., Ph.D., Chief Research & Development Officer (CRDO) of Astellas Pharma.

“我们非常高兴能与MRI达成谅解备忘录。安斯泰来制药致力于通过提供我们在研究和全球网络中获得的知识和经验，与学术界和初创公司共同推动创新理念和技术的发展，”安斯泰来制药首席研发官（CRDO）谷口忠昭医学博士表示。

“We expect that the signing of this MoU will further strengthen and accelerate drug discovery research by Japanese startups, ultimately leading to the creation of innovative medical solutions.”.

“我们预计，此谅解备忘录的签署将进一步加强和加速日本初创企业的药物发现研究，最终促成创新医疗解决方案的诞生。”

The new support will provide Japanese drug-discovery startups with early access to pharmaceutical-industry insights, enabling them to chart a path toward successful global development and potential out-licensing. This aligns with the

新的支持将为日本药物研发初创公司提供早期获取制药行业洞察的机会，帮助他们规划通往全球成功发展和潜在对外授权的道路。这与

Basic Policy on Economic and Fiscal Management and Reform 2024

2024年经济财政管理及改革基本方针

, which aims to improve domestic research and development environments while encouraging the participation of global pharmaceutical companies and venture capitalists in building a robust drug discovery ecosystem.

，该计划旨在改善国内研发环境，同时鼓励全球制药公司和风险资本家参与，建立一个强大的药物发现生态系统。

“We are pleased to partner with Astellas Pharma to support startups under the MEDISO initiative, and we are sure that this will be a groundbreaking step for Japan’s drug discovery ecosystem,” said Suzuki. “We are committed to leveraging the strengths of both companies to swiftly deliver innovative pharmaceuticals to patients in Japan and globally.”.

“我们很高兴与安斯泰来制药合作，支持MEDISO倡议下的初创企业，我们相信这将是日本药物发现生态系统的一个突破性步骤，”铃木表示。“我们致力于利用两家公司的优势，迅速为日本及全球的患者提供创新药物。”

Moving forward, MEDISO as a whole aims to collaborate with domestic and international business partners to support the global expansion of Japanese drug- discovery startups while encouraging global investors to invest in Japan’s burgeoning drug discovery field.

今后，MEDISO整体旨在与国内外商业伙伴合作，支持日本药物研发初创公司的全球扩展，同时鼓励全球投资者投资日本蓬勃发展的药物研发领域。

About Mitsubishi Research Institute, Inc.

关于三菱综合研究所

Mitsubishi Research Institute is one of Japan’s foremost think tanks. For over five decades, it has provided the public and private sectors with research and consulting services in fields spanning healthcare, the environment, energy, and digital transformation. This is accompanied by policy recommendations and the real-world application of solutions.

三菱综合研究所是日本最主要的智库之一。五十多年来，它在医疗保健、环境、能源和数字化转型等领域为公共和私营部门提供了研究和咨询服务。同时，还提供政策建议和解决方案的实际应用。

Mitsubishi Research Institute will continue to envision the future, resolve societal issues, and lead change to build a sustainable and prosperous world. For more information, please visit: .

三菱综合研究所将继续展望未来，解决社会问题，引领变革，构建可持续发展的繁荣世界。欲了解更多信息，请访问：。

www.mri.co.jp/en/

www.mri.co.jp/zh/

About Astellas Pharma Inc.

关于安斯泰来制药公司

Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need.

安斯泰来是一家全球生命科学公司，致力于将创新科学转化为对患者的 VALUE。我们在肿瘤学、眼科、泌尿科、免疫学和女性健康等疾病领域提供变革性疗法。通过我们的研发项目，我们正在为那些存在高度未满足医疗需求的疾病开拓新的医疗解决方案。

Learn more at .

了解更多，请访问。

www.astellas.com

www.astellas.com

.

。

Click below for a copy of the full press release

点击下面获取完整新闻稿的副本